US2011223194A1PendingUtilityA1
Vaccine
Est. expiryMay 8, 2018(expired)· nominal 20-yr term from priority
Inventors:Timothy Raymond HirstNeil Andrew WilliamsAndrew MorganAndrew Douglas WilsonLucy Amber Bird
A61P 31/00A61P 37/04A61P 31/16A61P 31/20A61P 31/12A61P 31/14A61P 31/22A61P 37/02A61K 2039/543A61K 39/39A61K 2039/55544C12N 2710/16634A61K 39/00Y02A50/30
31
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.
Claims
exact text as granted — not AI-modified1 . A vaccine composition comprising a therapeutically effective amount of Escherichia coli heat labile enterotoxin B subunit (EtxB), and an antigen, wherein the EtxB is free from whole toxin and is not linked to the antigen, wherein the antigen is a virus antigen from the herpes virus family.
2 . The composition according to claim 1 , wherein the virus antigen is an antigen of a virus selected from the group consisting of Herpes Simplex Virus-1 (HSV-1), Herpes Simplex Virus-2 (HSV-2), Epstein-Barr Virus (EBV), Varicella-zoster Virus (VZV), Cytomegalovirus (CMV), Human Herpes Virus-6 (HHV-6), Human Herpes Virus-7 (HHV-7) and Human Herpes Virus-8 (HHV-8).
3 . The composition according to claim 1 , wherein the virus antigen is an antigen of a virus selected from the group consisting of HSV-1, HSV-2, CMV or EBV.
4 . A vaccine composition comprising 50 and 100 μg of Escherichia coli heat labile enterotoxin B subunit (EtxB), wherein the EtxB is free from whole toxin, and an antigen, wherein the EtxB and antigen are not linked to form a single active agent, wherein the antigen is a virus antigen from the herpes virus family.
5 . The composition according to claim 4 , wherein the virus antigen is an antigen of a virus selected from the group consisting of Herpes Simplex Virus-1 (HSV-1), Herpes Simplex Virus-2 (HSV-2), Epstein-Barr Virus (EBV), Varicella-zoster Virus (VZV), Cytomegalovirus (CMV), Human Herpes Virus-6 (HHV-6), Human Herpes Virus-7 (HHV-7) and Human Herpes Virus-8 (HHV-8).
6 . The composition according to claim 4 , wherein the virus antigen is an antigen of a virus selected from the group consisting of HSV-1, HSV-2, CMV or EBV.Join the waitlist — get patent alerts
Track US2011223194A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.